703 related articles for article (PubMed ID: 30465214)
21. Targeting the myeloid checkpoint receptor SIRPα potentiates innate and adaptive immune responses to promote anti-tumor activity.
Kuo TC; Chen A; Harrabi O; Sockolosky JT; Zhang A; Sangalang E; Doyle LV; Kauder SE; Fontaine D; Bollini S; Han B; Fu YX; Sim J; Pons J; Wan HI
J Hematol Oncol; 2020 Nov; 13(1):160. PubMed ID: 33256806
[TBL] [Abstract][Full Text] [Related]
22. SIRPα-CD47 Immune Checkpoint Blockade in Anticancer Therapy.
Veillette A; Chen J
Trends Immunol; 2018 Mar; 39(3):173-184. PubMed ID: 29336991
[TBL] [Abstract][Full Text] [Related]
23. The regulation of CD47-SIRPα signaling axis by microRNAs in combination with conventional cytotoxic drugs together with the help of nano-delivery: a choice for therapy?
Beizavi Z; Gheibihayat SM; Moghadasian H; Zare H; Yeganeh BS; Askari H; Vakili S; Tajbakhsh A; Savardashtaki A
Mol Biol Rep; 2021 Jul; 48(7):5707-5722. PubMed ID: 34275112
[TBL] [Abstract][Full Text] [Related]
24. Bispecific antibody approach for EGFR-directed blockade of the CD47-SIRPα "don't eat me" immune checkpoint promotes neutrophil-mediated trogoptosis and enhances antigen cross-presentation.
Hendriks MAJM; Ploeg EM; Koopmans I; Britsch I; Ke X; Samplonius DF; Helfrich W
Oncoimmunology; 2020 Sep; 9(1):1824323. PubMed ID: 33299654
[TBL] [Abstract][Full Text] [Related]
25. The role of CD47-SIRPα immune checkpoint in tumor immune evasion and innate immunotherapy.
Li Z; Li Y; Gao J; Fu Y; Hua P; Jing Y; Cai M; Wang H; Tong T
Life Sci; 2021 May; 273():119150. PubMed ID: 33662426
[TBL] [Abstract][Full Text] [Related]
26. Elimination of tumor by CD47/PD-L1 dual-targeting fusion protein that engages innate and adaptive immune responses.
Liu B; Guo H; Xu J; Qin T; Guo Q; Gu N; Zhang D; Qian W; Dai J; Hou S; Wang H; Guo Y
MAbs; 2018; 10(2):315-324. PubMed ID: 29182441
[TBL] [Abstract][Full Text] [Related]
27. Targeting CD47 in Anaplastic Thyroid Carcinoma Enhances Tumor Phagocytosis by Macrophages and Is a Promising Therapeutic Strategy.
Schürch CM; Roelli MA; Forster S; Wasmer MH; Brühl F; Maire RS; Di Pancrazio S; Ruepp MD; Giger R; Perren A; Schmitt AM; Krebs P; Charles RP; Dettmer MS
Thyroid; 2019 Jul; 29(7):979-992. PubMed ID: 30938231
[No Abstract] [Full Text] [Related]
28. Discovery of high affinity, pan-allelic, and pan-mammalian reactive antibodies against the myeloid checkpoint receptor SIRPα.
Sim J; Sockolosky JT; Sangalang E; Izquierdo S; Pedersen D; Harriman W; Wibowo AS; Carter J; Madan A; Doyle L; Harrabi O; Kauder SE; Chen A; Kuo TC; Wan H; Pons J
MAbs; 2019; 11(6):1036-1052. PubMed ID: 31257988
[TBL] [Abstract][Full Text] [Related]
29. The CD47-SIRPα Immune Checkpoint.
Logtenberg MEW; Scheeren FA; Schumacher TN
Immunity; 2020 May; 52(5):742-752. PubMed ID: 32433947
[TBL] [Abstract][Full Text] [Related]
30. CD20-selective inhibition of CD47-SIRPα "don't eat me" signaling with a bispecific antibody-derivative enhances the anticancer activity of daratumumab, alemtuzumab and obinutuzumab.
van Bommel PE; He Y; Schepel I; Hendriks MAJM; Wiersma VR; van Ginkel RJ; van Meerten T; Ammatuna E; Huls G; Samplonius DF; Helfrich W; Bremer E
Oncoimmunology; 2018; 7(2):e1386361. PubMed ID: 29308308
[TBL] [Abstract][Full Text] [Related]
31. A homogeneous SIRPα-CD47 cell-based, ligand-binding assay: Utility for small molecule drug development in immuno-oncology.
Burgess TL; Amason JD; Rubin JS; Duveau DY; Lamy L; Roberts DD; Farrell CL; Inglese J; Thomas CJ; Miller TW
PLoS One; 2020; 15(4):e0226661. PubMed ID: 32240171
[TBL] [Abstract][Full Text] [Related]
32. CD47 is a novel potent immunotherapy target in human malignancies: current studies and future promises.
Tong B; Wang M
Future Oncol; 2018 Sep; 14(21):2179-2188. PubMed ID: 29667847
[TBL] [Abstract][Full Text] [Related]
33. Utilizing the BiTE (bispecific T-cell engager) platform for immunotherapy of cancer.
Stieglmaier J; Benjamin J; Nagorsen D
Expert Opin Biol Ther; 2015; 15(8):1093-9. PubMed ID: 25971805
[TBL] [Abstract][Full Text] [Related]
34. Progress of CD47 immune checkpoint blockade agents in anticancer therapy: a hematotoxic perspective.
Chen YC; Shi W; Shi JJ; Lu JJ
J Cancer Res Clin Oncol; 2022 Jan; 148(1):1-14. PubMed ID: 34609596
[TBL] [Abstract][Full Text] [Related]
35. IgA-Mediated Killing of Tumor Cells by Neutrophils Is Enhanced by CD47-SIRPα Checkpoint Inhibition.
Treffers LW; Ten Broeke T; Rösner T; Jansen JHM; van Houdt M; Kahle S; Schornagel K; Verkuijlen PJJH; Prins JM; Franke K; Kuijpers TW; van den Berg TK; Valerius T; Leusen JHW; Matlung HL
Cancer Immunol Res; 2020 Jan; 8(1):120-130. PubMed ID: 31690649
[TBL] [Abstract][Full Text] [Related]
36. Advances in the study of CD47-based bispecific antibody in cancer immunotherapy.
Zhang B; Li W; Fan D; Tian W; Zhou J; Ji Z; Song Y
Immunology; 2022 Sep; 167(1):15-27. PubMed ID: 35575882
[TBL] [Abstract][Full Text] [Related]
37. Functional characterization of the selective pan-allele anti-SIRPα antibody ADU-1805 that blocks the SIRPα-CD47 innate immune checkpoint.
Voets E; Paradé M; Lutje Hulsik D; Spijkers S; Janssen W; Rens J; Reinieren-Beeren I; van den Tillaart G; van Duijnhoven S; Driessen L; Habraken M; van Zandvoort P; Kreijtz J; Vink P; van Elsas A; van Eenennaam H
J Immunother Cancer; 2019 Dec; 7(1):340. PubMed ID: 31801627
[TBL] [Abstract][Full Text] [Related]
38. Is CD47 an innate immune checkpoint for tumor evasion?
Liu X; Kwon H; Li Z; Fu YX
J Hematol Oncol; 2017 Jan; 10(1):12. PubMed ID: 28077173
[TBL] [Abstract][Full Text] [Related]
39. SIRPα-antibody fusion proteins stimulate phagocytosis and promote elimination of acute myeloid leukemia cells.
Ponce LP; Fenn NC; Moritz N; Krupka C; Kozik JH; Lauber K; Subklewe M; Hopfner KP
Oncotarget; 2017 Feb; 8(7):11284-11301. PubMed ID: 28061465
[TBL] [Abstract][Full Text] [Related]
40. Genetic variation of human neutrophil Fcγ receptors and SIRPα in antibody-dependent cellular cytotoxicity towards cancer cells.
Treffers LW; Zhao XW; van der Heijden J; Nagelkerke SQ; van Rees DJ; Gonzalez P; Geissler J; Verkuijlen P; van Houdt M; de Boer M; Kuijpers TW; van den Berg TK; Matlung HL
Eur J Immunol; 2018 Feb; 48(2):344-354. PubMed ID: 28952147
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]